MX2020013320A - Inhibidores de ectonucleotidasa y métodos de uso de los mismos. - Google Patents
Inhibidores de ectonucleotidasa y métodos de uso de los mismos.Info
- Publication number
- MX2020013320A MX2020013320A MX2020013320A MX2020013320A MX2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A MX 2020013320 A MX2020013320 A MX 2020013320A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ectonucleotidase inhibitors
- ectonucleotidase
- inhibitors
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La invención se refiere a nuevos compuestos heterocíclicos y preparaciones farmacéuticas de los mismos. La invención se refiere además a métodos para tratar o prevenir el cáncer usando los nuevos compuestos heterocíclicos de la invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688225P | 2018-06-21 | 2018-06-21 | |
US201962827505P | 2019-04-01 | 2019-04-01 | |
PCT/US2019/038245 WO2019246403A1 (en) | 2018-06-21 | 2019-06-20 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013320A true MX2020013320A (es) | 2021-02-22 |
Family
ID=68981317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013320A MX2020013320A (es) | 2018-06-21 | 2019-06-20 | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. |
Country Status (16)
Country | Link |
---|---|
US (3) | US11078228B2 (es) |
EP (1) | EP3810617A4 (es) |
JP (1) | JP2021529172A (es) |
KR (1) | KR20210024561A (es) |
CN (1) | CN112888696B (es) |
AU (1) | AU2019288495B2 (es) |
BR (1) | BR112020025132B1 (es) |
CA (1) | CA3104088A1 (es) |
CL (1) | CL2020003339A1 (es) |
CO (1) | CO2021000049A2 (es) |
IL (1) | IL279475A (es) |
MX (1) | MX2020013320A (es) |
PH (1) | PH12020552214A1 (es) |
SG (1) | SG11202012001YA (es) |
TW (1) | TW202010750A (es) |
WO (1) | WO2019246403A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119284A1 (en) * | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
EP3787635A4 (en) | 2018-04-30 | 2022-03-02 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
MX2020013320A (es) | 2018-06-21 | 2021-02-22 | Calithera Biosciences Inc | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. |
TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑,其製備方法和應用 |
CN114008048A (zh) * | 2019-06-20 | 2022-02-01 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
MX2022005256A (es) | 2019-10-30 | 2022-08-25 | Oric Pharmaceuticals Inc | Inhibidores de cd73. |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
CN115873049B (zh) * | 2023-02-13 | 2023-05-02 | 北京先通国际医药科技股份有限公司 | 腺苷的制备方法及其用途 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960008669B1 (ko) | 1991-04-24 | 1996-06-28 | 야마사 쇼오유 가부시끼가이샤 | 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체 |
WO1994010128A1 (en) | 1992-11-02 | 1994-05-11 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
WO2008011406A2 (en) * | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
US8603998B2 (en) | 2007-11-07 | 2013-12-10 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
CA2684017A1 (en) | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
EP2590958B1 (en) | 2010-07-08 | 2015-08-26 | Life Technologies Corporation | In situ chemiluminescent substrates and assays |
CN102311472B (zh) | 2010-07-09 | 2014-09-03 | 神隆(昆山)生化科技有限公司 | 2-氯-9-(2’-脱氧-2’-氟-β-D-***呋喃糖基)-腺嘌呤的制备 |
EP2705031B1 (en) | 2011-05-03 | 2018-04-11 | Life Technologies Corporation | Flash and glow 1,2-dioxetanes |
ES2713566T3 (es) * | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
US10068577B2 (en) * | 2014-04-25 | 2018-09-04 | Dolby Laboratories Licensing Corporation | Audio segmentation based on spatial metadata |
JP6657182B2 (ja) | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療用のcd73阻害剤としてのプリン誘導体 |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
EP3322713B1 (en) * | 2015-12-03 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
EP3510040A4 (en) | 2016-09-09 | 2020-06-03 | Calithera Biosciences, Inc. | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE |
WO2018119284A1 (en) * | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
CN109503587B (zh) * | 2017-09-14 | 2022-01-11 | 辽宁利锋科技开发有限公司 | 双杂环三氮唑核苷类似物的抗肿瘤作用与应用 |
US11377469B2 (en) * | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
EP3787635A4 (en) * | 2018-04-30 | 2022-03-02 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
EP3810109A4 (en) * | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING CD73 |
MX2020013320A (es) | 2018-06-21 | 2021-02-22 | Calithera Biosciences Inc | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. |
CN114008048A (zh) | 2019-06-20 | 2022-02-01 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
-
2019
- 2019-06-20 MX MX2020013320A patent/MX2020013320A/es unknown
- 2019-06-20 JP JP2020570902A patent/JP2021529172A/ja active Pending
- 2019-06-20 AU AU2019288495A patent/AU2019288495B2/en active Active
- 2019-06-20 CN CN201980054369.1A patent/CN112888696B/zh active Active
- 2019-06-20 CA CA3104088A patent/CA3104088A1/en active Pending
- 2019-06-20 BR BR112020025132-1A patent/BR112020025132B1/pt active IP Right Grant
- 2019-06-20 KR KR1020217001701A patent/KR20210024561A/ko unknown
- 2019-06-20 US US16/447,159 patent/US11078228B2/en active Active
- 2019-06-20 EP EP19823042.7A patent/EP3810617A4/en active Pending
- 2019-06-20 SG SG11202012001YA patent/SG11202012001YA/en unknown
- 2019-06-20 WO PCT/US2019/038245 patent/WO2019246403A1/en active Application Filing
- 2019-06-21 TW TW108121817A patent/TW202010750A/zh unknown
-
2020
- 2020-12-16 IL IL279475A patent/IL279475A/en unknown
- 2020-12-18 PH PH12020552214A patent/PH12020552214A1/en unknown
- 2020-12-21 CL CL2020003339A patent/CL2020003339A1/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000049A patent/CO2021000049A2/es unknown
- 2021-06-28 US US17/359,990 patent/US11858957B2/en active Active
-
2023
- 2023-11-01 US US18/499,248 patent/US20240132533A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2021000049A2 (es) | 2021-04-19 |
TW202010750A (zh) | 2020-03-16 |
WO2019246403A1 (en) | 2019-12-26 |
US20240132533A1 (en) | 2024-04-25 |
US20190389899A1 (en) | 2019-12-26 |
BR112020025132B1 (pt) | 2023-10-10 |
EP3810617A4 (en) | 2022-06-29 |
SG11202012001YA (en) | 2021-01-28 |
JP2021529172A (ja) | 2021-10-28 |
CL2020003339A1 (es) | 2021-06-25 |
AU2019288495B2 (en) | 2024-02-08 |
EP3810617A1 (en) | 2021-04-28 |
US11078228B2 (en) | 2021-08-03 |
AU2019288495A1 (en) | 2021-01-28 |
BR112020025132A2 (pt) | 2021-03-23 |
KR20210024561A (ko) | 2021-03-05 |
US20230022922A1 (en) | 2023-01-26 |
CN112888696A (zh) | 2021-06-01 |
US11858957B2 (en) | 2024-01-02 |
IL279475A (en) | 2021-01-31 |
CN112888696B (zh) | 2024-04-16 |
PH12020552214A1 (en) | 2021-08-16 |
CA3104088A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
ZA202007007B (en) | Mcl-1 inhibitors | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
MX2020011528A (es) | Inhibidores heterociclicos sustituidos de ptpn11. | |
PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
MX2021008533A (es) | Inhibidores de la pcsk9 y metodos de uso de los mismos. | |
EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
MX2019005294A (es) | Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos. | |
MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. | |
MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. |